1. The spontaneous reporting system in the United States;Baum,1994
2. Regression Analysis of Count Data;Cameron,1998
3. Screening for unknown effects of newly marketed drugs;Carson,1994
4. Center for Drug Evaluation and Research, Food and Drug Administration, 1996a. Priority Review Policy, in the Manual of Policies and Procedures. MAPP 6020.3. Available at http://www.fda.gov/cder/mapp/6020-3.pdf.
5. Center for Drug Evaluation and Research, Food and Drug Administration, 1996b. The Clinical Impact of Adverse Event Reporting. A MedWatch continuing education article, October.